Handelsbanken Fonder AB decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 438,803 shares of the medical research company's stock after selling 1,545 shares during the quarter. Handelsbanken Fonder AB owned about 0.08% of Amgen worth $114,370,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of AMGN. AMF Tjanstepension AB boosted its holdings in shares of Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company's stock worth $38,825,000 after purchasing an additional 17,387 shares during the period. Swedbank AB boosted its holdings in shares of Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock worth $173,639,000 after purchasing an additional 5,751 shares during the period. Copeland Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter worth approximately $132,000. Foundations Investment Advisors LLC boosted its holdings in shares of Amgen by 11.5% in the 3rd quarter. Foundations Investment Advisors LLC now owns 16,656 shares of the medical research company's stock worth $5,367,000 after purchasing an additional 1,716 shares during the period. Finally, Calton & Associates Inc. boosted its holdings in Amgen by 18.7% during the 3rd quarter. Calton & Associates Inc. now owns 844 shares of the medical research company's stock valued at $272,000 after acquiring an additional 133 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.
Insider Transactions at Amgen
In other news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last quarter. 0.69% of the stock is currently owned by insiders.
Amgen Stock Performance
Amgen stock traded up $5.08 during trading hours on Friday, hitting $303.01. 3,260,757 shares of the stock traded hands, compared to its average volume of 3,124,757. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm's 50 day moving average price is $275.62 and its 200-day moving average price is $300.75. The stock has a market capitalization of $162.78 billion, a price-to-earnings ratio of 40.13, a P/E/G ratio of 2.55 and a beta of 0.56. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities analysts expect that Amgen Inc. will post 20.6 EPS for the current fiscal year.
Amgen Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.14%. Amgen's dividend payout ratio is presently 126.09%.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on AMGN shares. Piper Sandler boosted their price objective on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Wells Fargo & Company dropped their price objective on Amgen from $335.00 to $280.00 and set an "equal weight" rating for the company in a report on Friday, January 10th. UBS Group dropped their price objective on Amgen from $335.00 to $326.00 and set a "neutral" rating for the company in a report on Thursday, October 31st. StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Finally, Bank of America boosted their price objective on Amgen from $256.00 to $275.00 and gave the company an "underperform" rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $314.09.
Read Our Latest Analysis on Amgen
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
